Table 3.
MOUD entry, opioid overdose, and opioid use as a function of treatment arm and time.
| PRSSa (Nrand. = 40) | Control (Nrand. = 40) | Treatment Group Test Statistic | |
|---|---|---|---|
| Verified MOUDb Treatment Entry | |||
| 3-month follow-up, n (%) | 7 (17.5 %) | 4 (10.0 %) | X2(1) = 0.9, p = 0.33 |
| 6-month follow-up, n (%) | 13 (32.5 %) | 7 (17.5 %) | X2(1) = 2.4, p = 0.12 |
| 12-month follow-up, n (%) | 13 (32.5 %) | 7 (17.5 %) | X2(1) = 2.4, p = 0.12 |
| Self-reported Opioid Overdose | |||
| 3-month follow-up, n (%) | 1 (2.5 %) | 6 (15.0 %) | Fc = 0.048, p = 0.11 |
| 6-month follow-up, n (%) | 4 (10.0 %) | 12 (30.0 %) | X2(1) = 5.0, p = 0.03 |
| 12-month follow-up, n (%) | 5 (12.5 %) | 13 (32.5 %) | X2(1) = 4.6, p = 0.03 |
| Opioid-positive Urine Drug Screensd | |||
| 3-month follow-up, n (%) | 28 (93.3 %) | 30 (88.2 %) | CAe = 0.70, p = 0.68 |
| 6-month follow-up, n (%) | 29 (100.0 %) | 24 (100.0 %) | – |
| 12-month follow-up, n (%) | 20 (87.0 %) | 18 (85.7 %) | CA = 0.12, p = 1.00 |
| Self-reported Past Month Opioid Use Days | |||
| 3-month follow-up, n (%) | 21.6 (10.9) | 17.3 (12.1) | Wf = 1.4, p = 0.18 |
| 6-month follow-up, n (%) | 19.1 (10.5) | 19.3 (3.3) | W = 0.0, p = 0.99 |
| 12-month follow-up, n (%) | 17.7 (12.5) | 15.7 (13.5) | W = -0.3, p = 0.73 |
a
Peer Recovery Support Services; bMedication for Opioid Use Disorder; cF = Fisher’s Exact; dMethadone and buprenorphine excluded for participants enrolled in MOUD; eCA = Cochran-Armitage; fW = Wilcoxon.